Key Highlights

  • Pharming Group shares fell 19.35% to €0.8896 on July 30, 2026, according to London South East data timed at 13:01 UK
  • The company cut full-year 2026 revenue guidance to US$375-395 million from US$405-425 million, a reduction of about US$30 million
  • H1 2026 revenue fell 6% to US$162.7 million as RUCONEST sales dropped 12% to US$130.7 million, only partly offset by 37% growth in Joenja to US$32.0 million
  • Pharming attributed the downgrade to RUCONEST market dynamics, specialty-pharmacy inventory drawdowns and its planned exit from non-US markets
  • A US FDA decision on paediatric leniolisib is due by October 24, 2026, with further clinical readouts expected in Q4 2026

A Guidance Cut That Landed Heavily

Shares in Pharming Group (LSE:0QCO) fell sharply on Wednesday, July 30, 2026, dropping 19.35% to €0.8896 by early afternoon in London, according to London South East data timed at 13:01 UK time. The move followed the Dutch rare-disease drugmaker's second-quarter and first-half results the same morning, in which management lowered its revenue guidance for the year. A note for UK readers: Pharming is a Netherlands-headquartered company whose primary listings are on Euronext Amsterdam and the Nasdaq, where it trades through American Depositary Shares. The London line under ticker 0QCO is quoted in euros, not pence, so 0.8896 is roughly 89 euro cents per share, not a sterling price; the company reports in US dollars.

What Happened to the Shares

The decline was among the steepest single-day falls in Pharming's recent history and tracked its Amsterdam listing. At 07:00 CET on July 30, 2026, Pharming released its interim figures and revised down its outlook for the remainder of 2026. Management now expects full-year total revenues of US$375 million to US$395 million, implying growth of between zero and 5% on the prior year. That is a reduction of around US$30 million from the US$405 million to US$425 million guided at the start of the year, which had pointed to growth of 8% to 13%. For a company valued on its ability to grow two marketed medicines, a downgrade of that scale landed heavily.

Understanding the Business

Pharming Group is a commercial-stage biopharmaceutical company based in Leiden, the Netherlands, focused on treatments for rare, debilitating diseases. It earns revenue from two approved medicines. The larger is RUCONEST, a recombinant protein used to treat acute attacks of hereditary angioedema (HAE), a rare, potentially life-threatening genetic condition. It has historically supplied the bulk of group sales, chiefly in the United States. The second is Joenja (leniolisib), an oral medicine approved for activated PI3K delta syndrome (APDS), an ultra-rare inherited immune disorder and the company's designated growth engine. Pharming is also studying leniolisib in other primary immunodeficiencies and developing napazimone (KL1333) for primary mitochondrial disease. As a rare-disease specialist reliant on a small number of high-value products, shifts in any one medicine can move its shares materially.

The Latest Financial and Operational Developments

Second-quarter total revenues were US$90.2 million, down 3% on the US$93.2 million a year earlier. First-half revenues of US$162.7 million were 6% lower than the US$172.3 million of the prior-year period. The split between the two products tells the story. RUCONEST sales fell 10% in the quarter to US$72.3 million and 12% in the half to US$130.7 million. Joenja grew strongly, with quarterly sales up 40% to US$17.9 million and first-half sales up 37% to US$32.0 million, though not yet enough to offset the decline at the larger product. Pharming reported second-quarter net profit of US$1.6 million, down from US$4.6 million, with the first-half net loss narrowing to US$3.6 million from US$10.3 million. Cash and marketable securities stood at US$159.5 million at June 30, 2026, down from US$181.1 million at end-2025. The company also trimmed operating-expense guidance to US$315-320 million from US$330-335 million, partly cushioning the revenue downgrade.

What May Be Driving the Sell-Off

The most plausible driver is the guidance cut delivered alongside the results; no other company-specific news emerged that morning. Pharming attributed the lower outlook to factors affecting RUCONEST: challenging market dynamics, inventory drawdowns at specialty pharmacies, and its planned exit from non-US markets. The company had already flagged that withdrawal earlier in the year; first-quarter RUCONEST revenue had dropped to US$58.4 million from US$68.6 million for that reason. Investors had been asked to expect group revenue growth of up to 13% in 2026; the revised range points to no more than 5%. Because RUCONEST remains the larger contributor, faster-than-anticipated erosion there outweighs the percentage gains at Joenja. CEO Fabrice Chouraqui pointed to an active patient base at 93% of year-ago levels and new enrolments the company expects to help stabilize revenue, but the market gave greater weight to the reduced numbers.

Where the Growth Opportunity Lies

The clearest opportunity lies with Joenja, whose sales are growing at close to 40% year on year. Pharming reported 1,042 APDS patients identified globally, including 298 in the United States and 387 across core markets outside it, against 132 US patients on paid therapy at quarter-end, leaving headroom if diagnosis and access improve. Geographic expansion is under way: Joenja secured approval in Canada on July 8, 2026 and South Korea on July 10, 2026, both for patients aged 12 and over, launched in Germany from July 1, 2026, and is expected to launch in Japan in the third quarter. A US regulatory decision on leniolisib for younger APDS patients aged four to eleven carries a target action date of October 24, 2026.

The Concentration Risk Behind the Downgrade

The central risk is concentration. RUCONEST still generates most revenue, and its decline, driven by the non-US withdrawal, specialty-pharmacy inventory effects and market pressure, underlies the guidance cut; if that erosion proves faster or more durable than management expects, further downgrades cannot be ruled out. The HAE market is also evolving as newer oral on-demand therapies reshape treatment choices. Joenja, while growing, remains too small to carry the group alone and depends on continued diagnosis and reimbursement in each new market. The pipeline carries the usual clinical and regulatory uncertainty, and the cash balance fell over the half, so watching the burn rate matters.

What to Watch Next

Several dated milestones give checkpoints. Most immediate is the US Food and Drug Administration decision on leniolisib for children aged four to eleven, with a target action date of October 24, 2026; approval would widen the eligible population. Pharming has completed enrolment in two Phase II trials of leniolisib in primary immunodeficiencies, with data expected in the fourth quarter of 2026 and the potential to open a single registrational Phase III study, while FALCON pivotal-trial enrolment in napazimone should complete during 2026. Commercially, the questions are whether RUCONEST revenue stabilizes and whether Joenja's launches in Germany and Japan convert into meaningful sales.

Conclusion

The near-20% fall in Pharming Group (LSE:0QCO) on July 30, 2026 has a clear proximate driver: a roughly US$30 million cut to full-year revenue guidance, delivered with half-year results that showed its largest product, RUCONEST, in decline. The response reflects a reset of growth expectations, with the cost-guidance reduction offering only partial comfort. Joenja is growing quickly and gaining approvals, and the pipeline offers several dated catalysts, but that is set against heavy dependence on a shrinking RUCONEST franchise. Whether the move proves an overreaction or a justified re-rating will depend on the clinical and commercial trends due in the second half of 2026.